QUOTED. 23 October 2019. Rob Kowal.
Medtronic said that the pivotal trial for its implantable cardioverter defibrillator without a transvenous lead has begun. See what Rob Kowal, chief medical officer for Medtronic's cardiac and heart failure business, said about it here.
“We fully believe this is not just a health benefit for individual patients but is also going to be a benefit to the economic system as well, and we will be working to collect the data to support that." – Rob Kowal, chief medical officer for cardiac and heart failure business, Medtronic
- Find out more: Medtronic Expects EV ICD To Reduce ICD Complications, Costs
Click here for a free trial of Medtech Insight